| Lacy Diane Estes, APRN, FNP-C | |
|
26 3rd St, Belmont, MS 38827-7737 | |
| (662) 454-4520 | |
| (662) 454-4521 |
| Full Name | Lacy Diane Estes |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 26 3rd St, Belmont, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275148967 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 904090 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kindred At Home | Tupelo, MS | Home health agency |
| North Mississippi Medical Ctr Hha | Tupelo, MS | Home health agency |
| Tishomingo Health Services Inc | Iuka, MS | Hospital |
| Red Bay Hospital | Red bay, AL | Hospital |
| North Mississippi Medical Center | Tupelo, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tishomingo Health Services, Inc. | 2466354303 | 14 |
News Archive
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
The Developing Talkers literacy program has been so successful that the U.S. Department of Education has awarded $3.3 million to The University of Texas Health Science Center at Houston (UTHealth) to expand it.
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg.
Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.
› Verified 3 days ago
| Entity Name | Tishomingo Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548376700 PECOS PAC ID: 2466354303 Enrollment ID: O20040122000374 |
News Archive
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
The Developing Talkers literacy program has been so successful that the U.S. Department of Education has awarded $3.3 million to The University of Texas Health Science Center at Houston (UTHealth) to expand it.
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg.
Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.
› Verified 3 days ago
| Entity Name | North Mississippi Medical Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053469486 PECOS PAC ID: 6103736665 Enrollment ID: O20040127000582 |
News Archive
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
The Developing Talkers literacy program has been so successful that the U.S. Department of Education has awarded $3.3 million to The University of Texas Health Science Center at Houston (UTHealth) to expand it.
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg.
Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.
› Verified 3 days ago
| Entity Name | Pontotoc Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821103516 PECOS PAC ID: 6002895356 Enrollment ID: O20040719001336 |
News Archive
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
The Developing Talkers literacy program has been so successful that the U.S. Department of Education has awarded $3.3 million to The University of Texas Health Science Center at Houston (UTHealth) to expand it.
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg.
Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.
› Verified 3 days ago
| Entity Name | North Mississippi Gilmore Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225502370 PECOS PAC ID: 2961745195 Enrollment ID: O20190510000063 |
News Archive
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
The Developing Talkers literacy program has been so successful that the U.S. Department of Education has awarded $3.3 million to The University of Texas Health Science Center at Houston (UTHealth) to expand it.
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg.
Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lacy Diane Estes, APRN, FNP-C 26 3rd St, Belmont, MS 38827-7737 Ph: (662) 454-4520 | Lacy Diane Estes, APRN, FNP-C 26 3rd St, Belmont, MS 38827-7737 Ph: (662) 454-4520 |
News Archive
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
The Developing Talkers literacy program has been so successful that the U.S. Department of Education has awarded $3.3 million to The University of Texas Health Science Center at Houston (UTHealth) to expand it.
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg.
Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.
› Verified 3 days ago
Heather Larue Edmondson, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 102 3rd St, Belmont, MS 38827 Phone: 662-454-3401 | |
Whitney Bonner Sparks, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 26 3rd St, Belmont, MS 38827 Phone: 662-454-4520 Fax: 662-454-4521 | |
Dr. Toni Armstrong, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 8 Front St, Belmont, MS 38827 Phone: 662-454-1170 | |
Angela James, FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 26 3rd St, Belmont, MS 38827 Phone: 662-454-7170 | |
Lisa Collums Rhea, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 8 Front St, Belmont, MS 38827 Phone: 662-454-1170 Fax: 662-454-1062 | |
Misty Leigh Glidewell, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 8 Front St, Belmont, MS 38827 Phone: 662-454-1170 Fax: 662-454-1062 |